ReviewMolecular neurobiology2025
Targeting Ischemic Stroke with Neural Stem Cells: Insights into Endogenous Repair Mechanisms, Biomaterial-Based Delivery, and Exosome Therapies.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological diseases, such as stroke, are typically deemed refractory because of the adult mammalian brain's poor ability to self-repair and regenerate, resulting in irreparable cellular damage. Neural stem cells (NSCs) have distinct capabilities to regenerate themselves and differentiate into several types of neural lineage cells, including neurons and glial cells, making them valuable in the treatment of stroke. They are capable of differentiating into neurons and glial cells, which establish themselves within the integrated circuitry of neural networks and restore functions. NSCs can also facilitate beneficial alterations indirectly, by secreting neurotrophic factors and exosomes that promote neuronal survival, angiogenesis, and dampen inflammation. NSCs promote an endogenous adaptive immune response toward a neuroprotective state, which enhances repair processes and reduces the impact of ischemic inflammation. Nevertheless, significant obstacles faced by directly transplanted NSCs are their limited survival and unpredictable differentiation in vivo. In order to address the constraints of directly transplanted NSCs and considering the pathological characteristics of stroke including the loss of a certain cell type, extensive research has focused on investigating the possibility of enhancing the in vivo survival, migration, and differentiation of NSCs. In light of this, different strategies, such as preconditioning of NSCs, using NSC exosome, and also cell delivery by biomaterials, have gained significant interest. In this study, we delve into current advancements in harnessing NSC capacities to enhance neurogenesis and induce neuroprotection in stroke.
Indexed as
Identifiers
41273479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.